Skip to main content
Top
Published in: Netherlands Heart Journal 6/2019

Open Access 01-06-2019 | Cardiomyopathy | Original Article

Large next-generation sequencing gene panels in genetic heart disease: challenges in clinical practice

Authors: I. Christiaans, O. R. F. Mook, M. Alders, H. Bikker, R. H. Lekanne dit Deprez

Published in: Netherlands Heart Journal | Issue 6/2019

Login to get access

Abstract

Background

Next-generation sequencing gene panels are increasingly used for genetic diagnosis in inherited cardiac diseases. Besides pathogenic variants, multiple variants, variants of uncertain significance (VUS) and incidental findings can be detected. Such test results can be challenging for counselling and clinical decision making.

Methods

We present patient cases to illustrate the challenges that can arise when unclear genetic test results are detected in cardiogenetic gene panels.

Results

We identified three types of challenging gene panel results: 1) one or more VUS in combination with a pathogenic variant, 2) variants associated with another genetic heart disease, and 3) variants associated with a syndrome involving cardiac features.

Conclusion

Large gene panels not only increase the detection rates of pathogenic variants but also of variants with uncertain pathogenicity, multiple variants and incidental findings. Gene panel results can be challenging for genetic counselling and require proper pre-test and post-test counselling. We advise evaluation of challenging cases by a multidisciplinary team.
Literature
1.
go back to reference Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J. 2015;36:1367–70.CrossRef Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J. 2015;36:1367–70.CrossRef
2.
go back to reference Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31:2715–26.CrossRef Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31:2715–26.CrossRef
3.
go back to reference Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRef Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRef
4.
go back to reference MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469–76.CrossRef MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469–76.CrossRef
5.
go back to reference Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013;15:158–70.CrossRef Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013;15:158–70.CrossRef
6.
go back to reference Grove ME, Wolpert MN, Cho MK, Lee SS, Ormond KE. Views of genetics health professionals on the return of genomic results. J Genet Couns. 2014;23:531–8.CrossRef Grove ME, Wolpert MN, Cho MK, Lee SS, Ormond KE. Views of genetics health professionals on the return of genomic results. J Genet Couns. 2014;23:531–8.CrossRef
7.
go back to reference Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol. 2014;111:531–8. Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol. 2014;111:531–8.
8.
9.
go back to reference Burton H. Genetics and mainstream medicine. Cambridge: Report PHG Foundation; 2011. Burton H. Genetics and mainstream medicine. Cambridge: Report PHG Foundation; 2011.
10.
go back to reference Committee of Ministers CoE. Recommendation CM/Rec(2010)11 of the Committee of Ministers to member states on the impact of genetics on the organisation of health care services and training of health professionals. 2010. Committee of Ministers CoE. Recommendation CM/Rec(2010)11 of the Committee of Ministers to member states on the impact of genetics on the organisation of health care services and training of health professionals. 2010.
12.
go back to reference Fukuzawa K, Yoshida A, Onishi T, et al. Dilated phase of hypertrophic cardiomyopathy caused by Fabry disease with atrial flutter and ventricular tachycardia. J Cardiol. 2009;54:139–43.CrossRef Fukuzawa K, Yoshida A, Onishi T, et al. Dilated phase of hypertrophic cardiomyopathy caused by Fabry disease with atrial flutter and ventricular tachycardia. J Cardiol. 2009;54:139–43.CrossRef
13.
go back to reference Lukas J, Giese AK, Markoff A, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013;9:e1003632.CrossRef Lukas J, Giese AK, Markoff A, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013;9:e1003632.CrossRef
14.
go back to reference Bottillo I, D’Angelantonio D, Caputo V, et al. Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. Gene. 2016;577:227–35.CrossRef Bottillo I, D’Angelantonio D, Caputo V, et al. Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. Gene. 2016;577:227–35.CrossRef
15.
go back to reference Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet. 2013;50:228–39.CrossRef Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet. 2013;50:228–39.CrossRef
16.
go back to reference Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17:880–8.CrossRef Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17:880–8.CrossRef
17.
go back to reference Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:857–64.CrossRef Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:857–64.CrossRef
18.
go back to reference Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002;40:350–6.CrossRef Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002;40:350–6.CrossRef
19.
go back to reference Vernooy K, Sicouri S, Dumaine R, et al. Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm. 2006;3:1074–8.CrossRef Vernooy K, Sicouri S, Dumaine R, et al. Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm. 2006;3:1074–8.CrossRef
21.
go back to reference Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. 2015;15:936.CrossRef Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. 2015;15:936.CrossRef
22.
go back to reference Slade I, Subramanian DN, Burton H. Genomic education for medical professionals—the current UK landscape. Clin Med (Lond). 2016;16:347–52.CrossRef Slade I, Subramanian DN, Burton H. Genomic education for medical professionals—the current UK landscape. Clin Med (Lond). 2016;16:347–52.CrossRef
Metadata
Title
Large next-generation sequencing gene panels in genetic heart disease: challenges in clinical practice
Authors
I. Christiaans
O. R. F. Mook
M. Alders
H. Bikker
R. H. Lekanne dit Deprez
Publication date
01-06-2019
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 6/2019
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-019-1251-4

Other articles of this Issue 6/2019

Netherlands Heart Journal 6/2019 Go to the issue